<span id="test" class="text-size-large">By adopting ReDA as their centralised system, NHS Research Scotland (NRS) optimised governance processes, boosted multi-site trials, and gained real-time insights to drive clinical research success.</span>

About NHS Research Scotland  

NRS aims to ensure NHS Scotland provides the best environment to support excellence in clinical and translational research so patients can benefit from new and improved treatments. NRS is a partnership of all Scottish NHS Boards – who are responsible for planning and delivering healthcare services – and the Chief Scientist Office (CSO) of the Scottish Government.  

The challenge: inconsistent data capture and no centralised system

Historically, NRS captured data across its Health Boards in different ways, meaning both NRS and the CSO couldn’t easily obtain an accurate and usable data set of clinical trial activities across Scotland. Without a standardised and centralised system, this led to several challenges, and missed opportunities, including:

  • Difficulty in tracking clinical trial KPIs
  • Challenges around real-time monitoring to identify problems in trial delivery  
  • Difficulty in making strategic and evidence-based decisions  
  • Delays in setting up multi-site clinical trials across Health Boards

NRS needed a national solution to streamline all data management across its Scottish Health Boards, enabling deeper and more accurate insights for clinical trial activities. In 2009, ReDA – Infonetica’s Clinical Trial Management System (CTMS) went live. NRS and Infonetica have partnered ever since.

NRS standardised data capture and centralised the system to give an accurate national picture  

NRS and the CSO established the data points required to fulfil their objectives. Using ReDA’s configurability, they embedded a National Minimum Data Set into ReDA across all clinical stakeholders in Scotland.  

Today, with the standardised central system, NRS continues to quickly identify gaps in data and feed this back to the Health Boards, enabling them to correct mistakes and ensure data quality and compliance are upheld. Importantly, ReDA enables the Health Boards to invoice all funding by identifying incomplete financial data.  

Another benefit NRS has recognised with ReDA is saving 36 days a month across all Health Boards by centralising much of its data administration. This has delivered savings on average of 3 days a month from each of the boards’ administrative teams, freeing up their time to further focus on delivering clinical research.

ReDA has given us a much deeper view of our clinical trial data sets, enabling greater strategic insights for all activities happening across Scotland.  
Ian Anderson,  Information Services Manager

NRS tracks KPIs at a national level to effectively market Scotland for clinical trials

ReDA’s reporting gives NRS a clear picture of the typical clinical trial KPIs stakeholders track, such as how long it takes to complete governance and compliance checks, the time to recruit patients, and the capacity and performance of each Health Board.

These KPIs provide valuable insights supporting NRS to:

  • Position Scotland as a competitive nation to carry out clinical research  
  • Identify under-represented commercial sponsors enabling NRS to proactively encourage them to run trials in Scotland
With the data and intelligence that flows out of ReDA, we have been able to increase delivery of clinical research and maximise revenue.
Ian Anderson,  Information Services Manager  

NRS makes evidence-based decisions and identifies issues with real-time data  

Using ReDA, NRS makes smarter financial decisions. With real-time reporting, NRS can quickly identify underperforming studies early in the lifecycle and implement corrective actions such as assigning additional support.  

Another significant benefit has been improved budget allocation to each Health Board, leading to more effective use of government funding. These powerful budgeting insights further enable NRS to forecast potential revenue from trials facilitating forward investment planning.

Using ReDA, NRS has truly become a data-driven and evidence-based organisation. We allocate government budgets more effectively across the Health Boards thanks to the rich data from ReDA.
Ian Anderson,  Information Services Manager 

A streamlined system for setting up, delivering and tracking multi-site clinical trials

ReDA has reduced the time to set up trials and improved multi-site trial efficiency by:

  • Enabling NRS to simplify and expedite its internal processes for running and managing clinical trials  
  • Empowering each Health Board to conduct their own governance checks and approvals, and accessing real-time data insights  

This streamlined process has also further improved Scotland’s clinical trial KPIs such as accelerated approval and patient recruitment. Together, NRS and the Health Boards recruit up to 40,000 trial participants annually.  

I regularly generate data reports to help me track the CSO’s KPIs, providing a national overview and evidence to support the CSO’s office in answering First Minister’s Parliamentary Questions. ReDA has enabled me to rapidly provide these real-time data insights to support the CSO.
Mary McAuley,  Cardiovascular Network Manager

Summary and looking ahead  

Over the last 15 years, ReDA has empowered NRS to revolutionise its data set, resulting in greater strategic insights for all clinical activities across Scotland. Thanks to configuring consistent data capture and embedding a centralised system, NRS now has high-quality data for all clinical activities. This has led to an increase in the delivery of clinical research, maximised annual revenue of over £30 million each year, while supporting evidence-based decisions at a national level.  

Powered by ReDA, NRS has been able to further enhance Scotland’s competitive position in the clinical trial space. NRS continues to partner with Infonetica, to support the ever-changing needs of clinical trial delivery and ensure Scotland’s success in an increasingly competitive global market.